Trxade Health Inc (NASDAQ: MEDS), a leading health service IT company, reported a modest decline in its third-quarter revenues. Meanwhile, the company’s net loss narrowed sharply from the prior-year period.
Third-quarter revenues declined 6% year-over-year to $2.40 million. Despite that, Trxade’s net loss narrowed to $0.50 million or $0.06 per share in the September quarter from $1.30 million or $0.16 per share in the comparable period of fiscal 2021.
“These first nine months of 2022 have been an exciting and challenging time for TRxADE. We continue to focus the Company’s strategic plans and partnerships working towards creating sustainable value for our stockholders. I am pleased with the growth we have experienced in our TRxADE platform. We continue to achieve key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities,” said Trxade’s CEO Suren Ajjarapu.
Check this space to read management/analysts’ comments on Trxade’s Q2 2022 results
Shares of Trxade traded slightly lower early Tuesday, after closing the previous session lower. In the past six months, the stock experienced volatility.
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales
Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to